Patent ID: 8343485

Claim:
A sterile pharmaceutical composition for repair of a vascular injury caused by vascular insufficiency in a subject in need thereof comprising: (a) a vascular injury-repairing amount of a sterile chemotactic hematopoietic stem cell product, wherein the vascular injury-repairing amount is effective to repair a vascular injury caused by vascular insufficiency, the chemotactic hematopoietic stem cell product comprising an isolated nonexpanded population of autologous mononuclear cells comprising a subpopulation of CD34+ cells, which further contain a subpopulation of potent SDF-1-mobile CD34+/CXCR-4+ cells that have CXCR-4-mediated chemotactic activity; and (b) a stabilizing amount of serum, wherein the stabilizing amount of serum is at least 20% (v/v); wherein the pharmaceutical composition is formulated for administration parenterally through a catheter, and wherein the pharmaceutical composition is further characterized as having the following properties for at least 24 hours following acquisition of the chemotactic hematopoietic stem cell product when tested in vitro after passage through a catheter: (i) the subpopulation of CD34+ cells constitutes from about 1% to about 95% of the isolated nonexpanded population of autologous mononuclear cells; (ii) the subpopulation of CD34+ cells further contains a subpopulation of potent SDF-1 mobile CD34+/CXCR-4+ cells that have CXCR-4-mediated chemotactic activity; (iii) the subpopulation of CD34+ cells comprises from about 1% to about 95% viable CD34+ cells; and (iv) the subpopulation of CD34+ cells is able to form hematopoietic colonies in vitro.